KYNB Stock — Kyntra Bio Inc.: Cash, EV, Pipeline

What they do

Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. In January 2026, the Company announced its rebranding from “FibroGen, Inc.” to “Kyntra Bio, Inc.”, representing the next step of its transformation and focus on oncology and associated rare disease indications.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.73

Market cap

$15.1M

Cash

$95.3M

Enterprise value

-$5.2M

Balance sheet

Cash	$95.3M
Debt	$75.0M
Net cash	$20.3M
Enterprise value	-$5.2M
Basic shares	4.0M shares
Fully diluted shares	4.9M shares
Fully diluted market cap	$18.3M
Cash per share	$23.54
Quarterly burn	$4.0M
Cash runway	23.9 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

4.0M

Pre-funded warrants

0.0M

Options

0.5M

RSUs

0.1M

Warrants

0.0M

Converts

—

Conv preferred

0.0M

ESPP reserve

0.3M

FDSO

4.9M

Cap table as of 2026-07-31.

Price history

Loading KYNB daily closes…

Loading price history…

Next catalyst

FG-3246 · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	FG-3246 FG-3246 Phase 2 in metastatic castration-resistant prostate cancer	Phase 2	metastatic castration-resistant prostate cancer	Q4 2026
Nov 11 - Dec 23 in 37 mo	[89Zr]DFO-YS5	Phase 1	Bladder Cancer; Nerve Sheath Tumor; Nerve Sheath Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

FG-3246

Phase 2 · Active Modality: antibody-drug conjugate (ADC)

Target CD46

Partnerships Exclusively licensed from Fortis (option + evaluation agreement); Kyntra Bio controls and funds future R&D including the Phase 2 study and manufacturing

Indications

Metastatic castration-resistant prostate cancer (mCRPC) (Phase 2)

Status note CD46-targeting ADC. Ongoing Phase 2 monotherapy trial (NCT06842498): randomized, open-label dose-optimization in mCRPC patients progressed after ARPI therapy.

FG-3180

Stage not disclosed · Active Modality: PET imaging agent

Target CD46

Partnerships Exclusively licensed from Fortis (as part of FG-3246 program)

Indications

mCRPC (Stage not disclosed)

Status note CD46-targeting PET imaging agent being developed alongside FG-3246.

roxadustat

Approved · Active

Aliases EVRENZO

Target HIF prolyl hydroxylase

Partnerships Astellas (commercializes in Europe and Japan under Astellas Europe/Japan agreements); AstraZeneca U.S./RoW collaboration terminated Feb 25, 2024 (except South Korea); China operations sold to AstraZeneca Treasury Limited (Aug 29, 2025). Kyntra retains rights in US, Canada, Mexico and markets not held by AstraZeneca/Astellas

Indications

Anemia in chronic kidney disease (Approved)
Anemia associated with lower-risk MDS (high transfusion burden) (Phase 3)

Status note Approved in Europe, Japan, China and numerous other countries for anemia in CKD patients on dialysis. For lower-risk MDS anemia, Phase 3 protocol finalized; continuing trial preparations while evaluating internal development and potential partnership opportunities.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Roxadustat
Lead indication	Myelodysplastic Syndromes
Lead phase	Phase 3
Active trials	0
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05011188	Phase 2	Active, not recruiting	Collaborator	Rahul Aggarwal	—	Metastatic Castration-resistant Prostate Cancer; Prostate Cancer	—
NCT07664397	Phase 1	Not yet recruiting	Collaborator	Robert Flavell, MD, PhD	—	Bladder Cancer; Nerve Sheath Tumor; Nerve Sheath Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Rahul Aggarwal on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	0	-10,469	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

KYNB — Kyntra Bio Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

KYNB — Kyntra Bio Inc.